All material subject to strictly enforced copyright laws. © 2022 Managing IP is part of the Euromoney Institutional Investor PLC group.

The Netherlands: Swiss-type medical use claims and direct infringement

In the Dutch saga of the cross-border legal dispute between Novartis and Sun regarding commercialisation of zoledronic acid for treating osteoporosis, the Hague District Court in proceedings on the merits ruled in a verdict of April 5 2017 (ECLI:NL:RBDHA:2017:3430) that Sun directly infringes a Swiss-type medical use claim in European patent 1 296 689 B3, owned by Novartis.

It is the general opinion that Swiss-type medical use claims are in the category of claims directed to methods for manufacturing medicaments. In its decision, the District Court argued that the phrasing "for (the treatment of)" in the Swiss-type medical use claim at issue encompasses a mental element, namely knowledge of the fact, or foreseeability, that the manufactured zoledronic acid is to be marketed for the patented indication, namely treatment of osteoporosis.

Although the generic zoledronic acid was produced in India by a company in the Sun concern, the District Court expressly noted that this might not prevent Sun from literally infringing the Swiss-type medical use claim as a process claim in the Netherlands. The reason is that Sun provided the Indian manufacturer with specific instructions on packaging and patient leaflet information, held a manufacturing/import authorisation and executed product quality control in the Netherlands. Under these circumstances, Sun could potentially be considered a co-manufacturer according to the Court. Nevertheless, the ruling of direct infringement was based on the fact that Sun knew, or could foresee, that the medicament directly obtained by the Swiss-type medical use claim would be commercialised for the patented indication. Interestingly, with this decision, the District Court accepts that a Swiss-type medical use claim also, to some extent, confers purpose-limited product protection.

The mental element was considered to be present, for the reason that (1) Sun's marketing authorisation was inter alia obtained for the patented use, (2) the online SmPC and patient information leaflet did not contain the carve-out for the patented use, (3) the tender of health care insurance company VGZ, which Sun won, did not distinguish between patented and non-patented indications and (4) the size of the market for zoledronic acid, and the sales numbers, were such that it was foreseeable for Sun that the product was also sold for the patented indication.

Jetze Beeksma


Carnegieplein 5, 2517 KJ

The Hague

The Netherlands

Tel: +31 70 416 67 11

Fax: +31 70 416 67 99

more from across site and ros bottom lb

More from across our site

Sources say the Supreme Court’s decision to take on Sky v SkyKick puts uncertainty back into the mix, just when IP owners thought they knew what was what
Charles Feng, partner at East & Concord in Beijing, explains why filing for a trademark early is still a brand’s best bet
Counsel at IBM, Novartis, BMS and four other companies delve into whether the new Section 101 bill addresses their concerns
Clearance searches are especially important when counsel can’t rely on the USPTO’s opinion before key deadlines, say sources
VLSI case halted in Delaware; Netflix sues Bridgerton rip-off; Ex-GSK scientist escapes damages; US Copyright Office debuts new software; Abbvie scores Humira patent thicket win; Russia tables bill on illegal blocking of copyrighted content
An England and Wales High Court judgment over a disclosure error shows why law firms must never play a distant role when advising clients
Italy is in pole position to replace London as a central division host but must weather a political storm first
The senator’s proposed Section 101 legislation would cut down on exceptions to patent eligibility in the US
Ken Korea, founder of Colev Law and former head of US IP at Samsung, sets out the problems with anti-suit injunctions and the problem of getting rid of them
Thom Tillis and Patrick Leahy introduced a bill that would evaluate the need for recording examiner interviews, among other measures
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree